TDM 812

Drug Profile

TDM 812

Alternative Names: TDM812

Latest Information Update: 24 May 2016

Price : $50

At a glance

  • Originator 3-D Matrix
  • Developer 3-D Matrix; National Cancer Center (Tokyo); National Cancer Research Institute
  • Class Antineoplastics; Nucleic acids, nucleotides, and nucleosides; Peptides; Small interfering RNA
  • Mechanism of Action RNA interference; Small interfering RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top